Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug ...

CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

and is now in the final phase of the process for its name and ticker symbol change. This milestone marks a significant step forward in the company's corporate growth strategy, aligning its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and ...